Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05786872
Other study ID # MZhao-012
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 5, 2023
Est. completion date December 31, 2024

Study information

Verified date January 2023
Source Shanghai Mental Health Center
Contact Min Zhao
Phone 64387250
Email drminzhao@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of dual-target deep brain stimulation for treatment-resistant alcohol use disorder.


Description:

Total of 12 subjects from two centers ( Shanghai Mental Health Center and The Second Xiangya Hospital of Central South University ) who fit inclusion and exclusion criteria are recruited to undergo neurosurgical implantation of dual-target Deep Brain Stimulation (DBS) in bilateral nucleus accumbens (NAcc) and anterior limb of internal capsule (ALIC) on a certain date, the DBS system will be turned on for stimulation and parameters adjusted 10-14 days after implantation, treatment purposes are evaluated after DBS system has been turned on for 9-32 weeks. Primary efficacy is evaluated by major alcohol consumption rate, uncontrolled alcohol consumption days, maximum consecutive alcohol suspension days. Safety is evaluated by adverse events (AE) and device related AE, serious adverse events (SAE) and device related SAE, device deficiencies (DD) and device malfunction, physical examination and vital signs, laboratory examination, ECG, imageological examination, scale evaluation and early drop out ratio due to AE.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - 18 to 65 years old, no limit on sex. - Qualifies DSM-5 definition of alcohol use diagnosis, at least more than 4 terms. - Course of alcohol use disorder = 3 years. - Tried to quit drinking (de-addiction treatment under medical conditions, quit drinking by oneself, quit drinking each time = 1 week) but failed = 3 times. - Patient and relatives agree to accept systemic treatment of this study and sign Informed Consent Form after study purpose, content, expected treatment and risk etc. are fully explained and understood. Exclusion Criteria: - Patients who qualify DSM-5 serious mental disorder diagnosis standard (e.g. Schizophrenia spectrum, depression disorder, biphasic or related disorder, etc. ) - Patients who have other substance (tobacco excluded) abuse. - During screening period, answered 'yes' on question 4 or 5 in suicide intention term from Columbia-Suicide Severity Rating Scale, or had significant suicide intentions in the past 3 months, or patients who are considered by researchers to have suicide or violence risks. 4. Patients who have serious or unstable cardiovascular, respiratory, liver, kidney, hematological, endocrine, nervous system or other systemic diseases. - Patients who have implanted cochlear, pacemaker, cardiac defibrillator, single-sided or double-sided products of the same category, or the investigator evaluates patients have done surgeries within 6 months that can affect this study. - HIV positive patients. - Woman at pregnant or lactation period, or childbearing age woman test positive for HCG/urine pregnancy check; or patients who can't take effective contraception measures during trial; or patients who plan to be/make pregnant 3 months after the trial starts. - Patients who are participating other pharmaceutical or medical device clinical trials or have participated one in the past 3 months. - Patients who are considered unsuitable by investigators.

Study Design


Intervention

Device:
dual-target deep brain stimulation
DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.

Locations

Country Name City State
China Second Xiangya Hospital of Central South University Changsha Hunan
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (5)

Lead Sponsor Collaborator
Shanghai Mental Health Center Central South University, Huashan Hospital, SceneRay Corporation, Limited, Shanghai 6th People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Brain electrophysiology study(electroencephalogram) Electroencephalographic rhythms (theta and beta) were recorded. And theta/beta ratio was compared to before stimulation Before stimulation and parameter optimization period(1-8 weeks after stimulation)
Other Brain electrophysiology study(Local Field Potentials) Electrical signal strength was compared to before stimulation Before stimulation and parameter optimization period(1-8 weeks after stimulation)
Other PET-CT Before DBS implant, use Positron Emission Topography (PET) technology to study imaging of brain metabolism. Metabolism features include the amount of dopamine, gamma-aminobutyric acid, glutamate. Patients will be retested for PET after 6 months of implant. Before DBS implant, after 6 months of implant.
Primary Major alcohol use rate Calculation formula: 'major alcohol use' times / 56 (total observation times) * 100% 24 weeks
Primary Cumulated uncontrolled alcohol use days Definition: more than 3 times consecutive alcohol use (random draw) = 5 standard cups
One time uncontrolled alcohol use days: e.g. 3 times consecutive follow-up results = 5 standard cups, fourth time < 5 standard cups, then uncontrolled alcohol use days is 3 * 3 = 9 days
Cumulated uncontrolled alcohol use days: Total days of all uncontrolled alcohol use days throughout 24 weeks
24 weeks
Primary Maximum consecutive alcohol suspension days a) Marked as maximum days of 'Constant alcohol suspension' b) Note: i. Major alcohol use standard: Blow test positive and reported = 5 standard cups daily over the past 3 days. 1 standard cup = 10g of pure alcohol.
ii. Minor alcohol use standard: No matter blow test is positive or not, alcohol use is reported over past 3 days but less than 5 standard cups.
iii. Constant alcohol suspension standard: Blow test negative and no alcohol use reported over past 3 days.
24 weeks
Secondary Alcohol use volume 9-32 weeks after stimulation, change in monthly average alcohol use volume compared to baseline. (Record in every follow-up according to participants. Record alcohol type, amount and experience when drinking throughout 9-32 weeks after stimulation. Increased value implies worse result and reduce of alcohol use volume indicates improvement. 24 weeks
Secondary Cumulated alcohol suspension days total value of 'Constant alcohol suspension' days after 9-32 weeks of stimulation. 24 weeks
Secondary Subjective alcohol urge Change in alcohol urge Visual Analogue Score compared to baseline. ( 0 is no urge, 10 is extreme urge) At 12, 20 and 32 weeks of stimulation
Secondary Alcohol abstinence Change in CIWA-Ar score compared to baseline. At 12, 20 and 32 weeks of stimulation
Secondary Sleep condition Pittsburgh Sleep Quality Index score compared to baseline. At 12, 20 and 32 weeks of stimulation
Secondary Emotion condition Hamilton Anxiety Scale-17 and Hamilton Depression Scale score compared to baseline. At 12, 20 and 32 weeks of stimulation
Secondary Social functions SDSS score compared to baseline. At 12, 20 and 32 weeks of stimulation
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A